Walleye Capital
KRYS icon

Walleye Capital’s Krystal Biotech KRYS Stock Holding History

Walleye Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46K Sell
12
-342
-97% -$102K ﹤0.01% 4545
2026
Q1 		$91.4K Buy
+354
New +$94.2K ﹤0.01% 3701
2024
Q4 		– Sell
-97
Closed -$17.2K – 5212
2024
Q3 		$17.7K Buy
+97
New +$18.7K ﹤0.01% 4839

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Walleye Capital's KRYS Position: Q2 2026 in Review

Walleye Capital reduced its Krystal Biotech (KRYS) stake by 97% in Q2 2026, selling an estimated $102K and leaving 12 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4545.

Walleye Capital first reported a position in KRYS in Q3 2024 and has held it in 3 quarters since. The position peaked at $91.4K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Walleye Capital held 12 shares of Krystal Biotech worth $4.46K as of Q2 2026.
  • Walleye Capital sold 342 Krystal Biotech shares in Q2 2026, an estimated $102K.
  • Krystal Biotech made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4545 holding.
  • Walleye Capital first reported a position in Krystal Biotech in Q3 2024 and has held it in 3 quarters since.
  • Walleye Capital's Krystal Biotech position peaked at $91.4K in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.